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We performed a two-tiered, whole-genome association study of Parkinson disease (PD). For tier 1, we individually
genotyped 198,345 uniformly spaced and informative single-nucleotide polymorphisms (SNPs) in 443 sibling pairs
discordant for PD. For tier 2a, we individually genotyped 1,793 PD-associated SNPs ( in tier 1) and 300P ! .01
genomic control SNPs in 332 matched case–unrelated control pairs. We identiﬁed 11 SNPs that were associated with
PD ( ) in both tier 1 and tier 2 samples and had the same direction of effect. For these SNPs, we combinedP ! .01
data from the case–unaffected sibling pair (tier 1) and case–unrelated control pair (tier 2) samples and employed
a liberalization of the sibling transmission/disequilibrium test to calculate odds ratios, 95% conﬁdence intervals,
and P values. A SNP within the semaphorin 5A gene (SEMA5A) had the lowest combined P value (Pp 7.62 #
). The protein encoded by this gene plays an important role in neurogenesis and in neuronal apoptosis, which5610
is consistent with existing hypotheses regarding PD pathogenesis. A second SNP tagged the PARK11 late-onset PD
susceptibility locus ( ). In tier 2b, we also selected for genotyping additional SNPs that were55Pp 1.70 # 10
borderline signiﬁcant ( ) in tier 1 but that tested a priori biological and genetic hypotheses regarding sus-P ! .05
ceptibility to PD ( SNPs). In analysis of the combined tier 1 and tier 2b data, the two SNPs with the lowestnp 941
P values ( ; ) tagged the PARK10 late-onset PD susceptibility locus. Independent56 55Pp 9.07 # 10 Pp 2.96 # 10
replication across populations will clarify the role of the genomic loci tagged by these SNPs in conferring PD
susceptibility.
Introduction
Association-based genome scans provide localizing in-
formation that is much more precise (often extending
over a few thousand base pairs) than the corresponding
information from linkage-based studies (which often ex-
tend over many millions of base pairs). To date, there
has been only one published high-resolution genome
scan for association for any human disease (Klein et al.
2005). Here, we report the results of a high-resolution,
whole-genome association study of Parkinson disease
(PD [MIM 168600]). Our ﬁndings contribute to the cre-
ation of a genomic predisposition map for PD, and we
illustrate a tiered genotyping approach that can be ap-
plied to the study of other complex diseases.
Material and Methods
We performed a high-resolution, whole-genome asso-
ciation study of PD, using a two-tiered genotyping ap-
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proach (tier 1 and tiers 2a and 2b). All methods of the
study were approved by the investigational review board
of the Mayo Clinic.
Tier 1
For tier 1, we included sibling pairs that were discor-
dant for PD. Cases were enrolled prospectively from the
clinical practice of the Department of Neurology of the
Mayo Clinic in Rochester, MN, from June 1996 through
May 2004. They all resided within Minnesota or one of
the surrounding four states (Wisconsin, Iowa, South Da-
kota, or North Dakota). All cases underwent a standard-
ized clinical assessment performed by a neurologist sub-
specialized in movement disorders. Cases had at least
two of four cardinal signs of parkinsonism (rest tremor,
rigidity, bradykinesia, and/or postural instability) and no
features atypical for PD (such as unexplained upper mo-
tor neuron signs or cerebellar signs). When nonmotor
manifestations such as dysautonomia or dementia were
present, they were mild and occurred late in the disease
course. Subjects with secondary causes of parkinsonism
(e.g., history of neuroleptic exposure, encephalitis, or
multiple strokes) were excluded. All patients treatedwith
a daily dosage total of1 g of levodopa (in combination
with carbidopa) had a more than minimal improvement
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Table 1
Distribution of Gap Sizes between Adjacent
Informative Tier 1 SNPs, within Chromosomal
Contigs from NCBI Build 34
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
in parkinsonism symptoms and signs. We obtained a
genealogical history from all cases, and, when permitted,
we contacted available siblings for a telephone inter-
view, to exclude parkinsonism via a validated screening
instrument (Rocca et al. 1998). For cases, we obtained
blood after a clinical assessment performed either at the
Mayo Clinic or in the subjects’ homes. For siblings who
screened negative for PD (i.e., who had none of the fol-
lowing: prior diagnosis of PD, prior treatment with levo-
dopa, or three or more of nine symptoms), we obtained
blood via mail-in kits (we did no clinical assessment).
All subjects provided written informed consent; their
whole blood was obtained, via venipuncture, for DNA
extraction (via the Puregene method [Gentra Sciences])
and storage. Cases werematched to a single participating
sibling, without PD or parkinsonism, ﬁrst by sex (when
possible) and then by closest age.
For each subject (matched discordant sibling pairs),
∼1 mg of DNA was shipped to Perlegen Sciences for
laboratory study. Whole-genome ampliﬁcation was per-
formed as described elsewhere (Dean et al. 2002). For
each subject, DNA was individually genotyped, for a set
of 248,535 SNPs, with unique positions on National
Center for Biotechnology Information (NCBI) build 34.
These SNPs were selected to have relatively uniform
spacing across the genome and to preferentially in-
clude haplotype-deﬁning common SNPs from the Perle-
gen haplotype map (Patil et al. 2001). Details regarding
the distribution of genomic gaps is provided in table 1.
The genotyping platform employed high-density oligo-
nucleotide, photolithographic microarrays (DNA chips),
such that one hybridization yielded genotypes for 85,000
SNPs in a single individual.
We performed a liberalization of the sibling transmis-
sion/disequilibrium test (sTDT) (Schaid and Rowland
1998) to identify SNPs that had signiﬁcant allele-fre-
quency differences in cases versus unaffected siblings,
adjusting the analyses for age and sex. For each SNP,
we calculated odds ratios (ORs), 95% CIs, and P values
(using a log-additive or “trend” model).
Tier 2
For tiers 2a and 2b, we individually genotyped case–
unrelated control pairs. Cases were enrolled as for tier
1 but had no siblings available. Unrelated controls were
identiﬁed via random digit dialing from the same ﬁve-
state region as the cases and were screened negative for
parkinsonism via the same validated telephone instru-
ment as for siblings in tier 1. DNA was collected at the
time of clinical assessment for cases and via mail-in kits
for controls. Case–unrelated control pairs were matched
for sex and age (3 years). DNA was again shipped to
Perlegen Sciences for whole-genome ampliﬁcation and
genotyping. The genotyping for tiers 2a and 2b was per-
formed using customized oligonucleotide microarrays.
For tier 2a, a subset of SNPs that were associated with
PD ( in tier 1) were genotyped. An additionalP ! .01
predeﬁned set of 311 SNPs was genotyped for genomic
control (Hinds et al. 2004). Conditional logistic regres-
sion analyses were performed, to test for and model as-
sociations between the SNPs and PD. The analyses were
adjusted for age and sex, as appropriate. We calculated
ORs, 95% CIs, and P values (as for tier 1, using a log
additive or “trend” model). We also checked for popu-
lation structure, using the genomic-control method (Dev-
lin and Roeder 1999; Bacanu et al. 2000; Devlin et al.
2004). This method treats the subjects as unmatched and
does not include adjustments for covariates; however, it
should still provide guidelines for assessing the degree
of stratiﬁcation in tier 2. For the SNPs associated with
PD ( ) in both the tier 1 and 2a analyses, weP ! .01
pooled data for the case–unaffected sibling and case–
unrelated control pairs and again analyzed the data, us-
ing a liberalization of the sTDT (Schaid and Rowland
1998). This allowed us to maximize statistical power for
the analyses to obtain a more precise ranking of repli-
cated SNPs by ascending P values and a more precise
estimate of ORs and 95% CIs.
For tier 2b, we also selected for genotyping additional
SNPs that in tier 1 were only borderline signiﬁcant but
that tested a priori biological or genetic hypotheses re-
garding genomic susceptibility to PD. These SNPs did
not achieve a P value !.01 in the tier 1 sample overall.
However, some of these SNPs (1) had P values !.001
in tier 1 strata deﬁned by sex or by median age at study;
(2) had P values !.05 and were positioned within 10
kb of the linkage-derived candidate genes a-synu-
clein (SNCA [MIM 163890]), parkin (MIM 602544),
ubiquitin carboxy-terminal hydrolase L1 (UCHL1 [MIM
191342]), microtubule-associated protein t (MAPT
[MIM 157140]), oncogene DJ1 (DJ1 [MIM 602533]),
and PTEN-induced kinase 1 (PINK1 [MIM 608309]);
(3) had P values !.05 and were positioned within ad-
ditional loci linked to PD (i.e., PARK3 [MIM 602404],
PARK8 [MIM 607060], PARK9 [MIM 606693],
PARK10 [MIM 606852], PARK11 [MIM 607688]); (4)
had P values !.05 and were positioned within exons or
within 10 kb 5′ of the transcript, genomewide; or (5)
were redundant tags of European American linkage-dis-
equilibrium bins (Hinds et al. 2005) highlighted by some
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Table 2
Demographic and Clinical Characteristics (Tiers 1 and 2)
CHARACTERISTICS
FINDINGS FOR SUBJECTS
Tier 1 Tier 2
PD Cases Siblings PD Cases Controls
No. (%) of subjects: 443 (100) 443 (100) 332 (100) 332 (100)
Male 271 (61.2) 214 (48.3) 194 (58.4) 193 (58.1)
Female 172 (38.8) 229 (51.7) 138 (41.6) 139 (41.9)
Median age (range), in years, at PD onset 61 (31–94) … 63 (36–88) …
Median age (range), in years, at time of study 68 (33–96) 66 (29–90) 68 (42–90) 67 (42–91)
Percentage of subjects with family history of PDa 20.5 … 14.9 …
No. (%) of subjects with parental region of origin:
Both parents of European origin: 381 (86.0) 363 (81.9) 269 (81.0) 272 (81.9)
Both parents northern Europeanb 111 (29.1) 100 (27.5) 84 (31.2) 83 (30.5)
Both parents central Europeanc 145 (38.1) 135 (37.2) 96 (35.7) 84 (30.9)
Both parents southern Europeand 3 (.8) 3 (.8) 2 (.7) 3 (1.1)
Both parents European, mixed region 122 (32.0) 125 (34.4) 87 (32.3) 102 (37.5)
Only one parent of European origine 39 (8.8) 39 (8.8) 43 (13.0) 35 (10.5)
One parent declared “American”f 2 (.5) 1 (0.2) 1 (.3) 4 (1.2)
Both parents declared “American” 18 (4.1) 23 (5.2) 12 (3.6) 19 (5.7)
Both parents Asian … 1 (.2) 1 (.3) …
Origin unknown 3 (.7) 16 (3.6) 6 (1.8) 2 (.6)
a Family history was deﬁned as having at least one affected ﬁrst-degree relative; for tier 1, 90/439 cases had a
family history of PD (information was missing for 4); for tier 2, 48/322 cases had a family history of PD (information
was missing for 10).
b “Northern European” includes Scandinavian, Swedish, Norwegian, Finnish, Danish, Irish, or British origins.
c “Central European” includes French, Belgian, Dutch, Swiss, Luxemburgian, German, Austrian, Hungarian,
Polish, Czechoslovakian, or Russian origins.
d “Southern European” includes Italian, Spanish, Portuguese, Greek, or Yugoslavian origins.
e Includes subjects for whom origin of one parent is unknown.
f These subjects were all European Americans and not Native Americans.
of the above criteria. We note that the tier 2b SNP se-
lection predated the discovery of mutations in the leu-
cine-rich repeat kinase 2 gene (LRRK2 [MIM 609007])
as the cause of PARK8-linked parkinsonism (although
SNPs within the gene were indeed selected and geno-
typed). We tested the association of these tier 2b SNPs
with PD in the combined samples, using a liberalization
of the sTDT (as above).
Results
Tier 1
For tier 1, we genotyped 443 case–unaffected sibling
pairs. Table 2 summarizes demographic and clinical
characteristics of the sample. For the 248,535 SNPs se-
lected, the genotyping call rate was 180% for each of
220,143 SNPs. Of these SNPs, 205,031 (93%) were
polymorphic within the study sample. The Hardy-Wein-
berg equilibrium (HWE) P value was 1.001 in con-
trols for 198,345 SNPs (97% of polymorphic SNPs,
with an average gap between adjacent SNPs of 12,363
bp). Ultimately, for these subjects and informative SNPs,
172,420,019 genotype calls (98.1% of possible geno-
types) were made.We regenotyped, in triplicate, 96 SNPs
for each subject, with 99.8% concordance of genotypes.
The concordance of genotypes called by the oligonucleo-
tide array platform, as compared with genotypes called
by other platforms employed as part of the multicenter
HapMap project, was 99.5% (Hinds et al. 2005).
As a sensitivity analysis and to assess the genomic
coverage of the informative SNPs, we determined our
statistical power to detect unassayed, disease-associated
variants with this SNP collection. Speciﬁcally, we pre-
viously genotyped these same SNPs in a different sample
of European Americans who were also sequenced across
selected genes by the SeattleSNPs Program for Genomic
Applications (PGA) (SeattleSNPs) (Hinds et al. 2005).
Our metric of coverage was the mean r2 value for any
common PGA SNP (minor-allele frequency 110%) with
the most-correlated SNP in the same region from the
198,345 informative SNPs. The statistical power to de-
tect an unassayed, disease-associated allele indirectly by
use of a correlated allele of an assayed SNP is related
to r2. Speciﬁcally, the power to detect an association
indirectly in N samples is equivalent to the power to
detect it directly in Nr2 samples (Pritchard and Przewor-
ski 2001). Despite our assaying only 3.3% of all of the
common SNPs in these intervals (and only 1% of the
less common SNPs), the mean r2 for unassayed SNPs
was 0.57.
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Table 3
Column Descriptions for Text Files 1 and 2
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
There were 1,862 SNPs that were associated with PD
in tier 1 ( ), after exclusion of SNPs with fewerP ! .01
than nine discordances between sibling pairs (SNPs for
which ORs could not be reliably estimated). We provide
details for all informative tier 1 SNPs (including their
dbSNP reference sequence identiﬁcation numbers, gene
names, case and control allele frequencies, ORs, 95%
CIs, and P values) in tab-delimited text ﬁle 1 (online
only); the columns are described in table 3.
Tier 2
For tier 2a, we genotyped 332 case–unrelated con-
trol pairs. Table 2 summarizes demographic and clinical
characteristics for these samples. Genotypes and analy-
ses were attempted for the 1,862 SNPs selected in tier
1 and for 311 genomic control SNPs. Of these, geno-
typing call rates of 180% and HWE P values 1.001 (in
controls) were achieved for 1,793 SNPs. We were able
to call successfully 1,176,772 (99% of possible) geno-
types for these SNPs.
To assess the impact of population structure on tier
2 associations, trend tests were performed on the ge-
nomic control SNPs. The mean trend test statistic over
the genomic control SNPs, lm, was 0.96, which is less
than the expected value of 1 for no population structure
(Devlin et al. 2004). Therefore, there was no indication
of substantial confounding due to population structure
bias.
There were 26 SNPs with P values !.01 in both tier
1 and tier 2a. Of these SNPs, 11 had nominal P val-
ues !.01 and the same direction of the effect in tier
1 and tier 2a (termed “replicated SNPs”). A SNP
(rs7702187) within the semaphorin 5A gene (SEMA5A
[MIM 609297]) had the lowest P value (OR 1.74;
95% CI 1.36–2.24; ). A second SNP6Pp 7.62 # 10
(rs10200894) tagged the PARK11 late-onset PD sus-
ceptibility locus (OR 1.84; 95% CI 1.38–2.45; Pp
). Table 4 lists the 11 replicated SNPs, in-51.70 # 10
cluding their dbSNP reference sequence identiﬁcation
numbers and, when applicable, the corresponding gene
ontology annotation of nearby genes. The SNPs are or-
dered by ascending combined P values. We provide ad-
ditional results for the tier 2a SNPs (including their
dbSNP reference sequence identiﬁcation numbers and
gene names and, for the combined samples, the case and
control allele frequencies, ORs, 95% CIs, and P values),
in tab-delimited text ﬁle 2 (online only); the columns are
described in table 3. The 11 replicated SNPs from tiers
1 and 2a (table 4) had 20 neighboring SNPs within a
distance of 15 kb of the reported data. None of these
20 SNPs were signiﬁcant enough to be selected for in-
clusion in tier 2a. However, 6 of the 20 SNPs had tier
1 P values !.1 ( on a binomial test), and 14 ofPp .011
these 20 had P values !.2 ( ). Thus, there6Pp 1.8 # 10
is evidence of correlations among neighboring SNPs.
Table 5 summarizes the rationale for inclusion of the
tier 2b SNPs, primarily on the basis of a priori biologi-
cal and genetic hypotheses regarding susceptibility to
PD. We considered 975 tier 2b SNPs. Of these, geno-
typing call rates of 180% and HWE P values 1.001 in
controls were achieved for 941 SNPs. We were able to
call successfully 617,257 (99% of maximum possible)
genotypes for these SNPs. Of these, the two SNPs
(rs682705 and rs7520966) with the lowest combined
tier 1 and tier 2b P values ( , OR 0.66,6Pp 9.07 # 10
95%CI 0.54–0.79 and OR 0.67, 95%5Pp 2.96 # 10
CI 0.55–0.81, respectively) tagged the PARK10 late-on-
set PD susceptibility locus. The r2 value between the two
SNPs was 0.993 (highly correlated). We provide addi-
tional results for the tier 2b SNPs (including their dbSNP
reference sequence identiﬁcation numbers, gene names,
case and control allele frequencies, ORs, 95% CIs, and
P values) in tab-delimited text ﬁle 2 (online only).
Discussion
Twin studies and familial aggregation studies have sug-
gested that the genetic contribution to PD is small and
limited to younger-onset cases (Rocca et al. 2004;Wirde-
feldt et al. 2004). However, parametric linkage studies
have assigned 11 loci to PD, and causal mutations have
been identiﬁed in six genes (SNCA, parkin,UCHL1,DJ1,
PINK1, and LRRK2) (Polymeropoulos et al. 1997; Ki-
tada et al. 1998; Leroy et al. 1998; Bonifati et al. 2003;
Valente et al. 2004; Zimprich et al. 2004). Nonpara-
metric linkage studies have also assigned the locus con-
taining the MAPT gene to PD (Martin et al. 2001).
Whereas mutations in these genes only rarely cause PD,
common variations in some of these genes may confer
susceptibility with a more sizable population-attributa-
ble risk (Farrer et al. 2001;West et al. 2002;Maraganore
et al. 2004; Mamah et al. 2005; Mueller et al. 2005).
However, the search for PD susceptibility genes has been
largely limited to the candidate-genes approach.
Our study is unique because we aimed to discover
common PD susceptibility gene variants via a whole-
genome association design. Despite the low heritability
of PD, we have nominated several new susceptibility
genes for PD (table 4). Findings for the SEMA5A gene
are particularly noteworthy and highlight the apoptosis
pathway (Tatton et al. 2003).
The SEMA5A gene (sema domain, seven thrombo-
spondin repeats [type 1 and type 1–like], transmem-
brane domain [TM], and short cytoplasmic domain,
[semaphorin] 5A) has not been previously implicated in
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Table 5
Criteria for SNPs Selected for Genotyping in Tier 2
Category Description No. of SNPs
1 in tier 1 overall analysisP ! .01 1,862
2 in tier 1 age- or sex-stratiﬁed analysesP ! .001 188
3 in tier 1 overall analysis, within 10 kb of the six linkage-derived candidate genesP ! .05
(SNCA, PARK2, UCHL1, MAPT, DJ1, and PINK1)
8
4 in tier 1 overall analysis, within additional PARK linkage loci for which genes have notP ! .05
been cloned (PARK3, PARK8, PARK9, PARK10, and PARK11)
145
5 in tier 1 overall analysis, within exons or within 10 kb 5′ of the transcript, genomewideP ! .05 589
6 Genomic control SNPs 311
7 Other SNPs in linkage disequilibrium with those passing criteria 1 and 2 45
Total 3,148
PD. Although the effect size is small (OR 1.7; 95% CI
1.36–2.24), the disease-associated allele occurs with suf-
ﬁcient frequency to confer a sizable population-attrib-
utable risk (minor-allele for unre-frequencyp 19.6%
lated controls). This gene maps to the deletion candidate
interval for cri du chat syndrome. This chromosomal
deletion syndrome is associated with severe abnormal-
ities in brain development, with resultant mental retar-
dation (Simmons et al. 1998). The encoded semaphorin
protein has receptor activity and contributes to neuro-
genesis and apoptotic processes. It elicits multiple func-
tional responses through its receptor plexin-B3 (Arti-
giani et al. 2004). Speciﬁcally, semaphorins may play a
role in the development of the mesencephalic dopamine
neuron system (Kawano et al. 2003). They are also pos-
itive mediators of dopamine-induced apoptosis; anti-
bodies directed against semaphorins inhibit dopa-
mine-induced neuronal death (Shirvan et al. 1999,
2000; Barzilai et al. 2000). The expression of sema-
phorin genes is abnormal in Alzheimer disease, which
shares clinical, pathological, and etiological features
with PD (Hirsch et al. 1999). It has also been suggested
in a rat model of PD that the neuroprotective effects of
vascular endothelial growth factor may be mediated via
semaphorin inhibition (Yasuhara et al. 2004). To date,
there have been no clinical studies of semaphorin in-
hibitors as neuroprotective therapy for PD. Our genetic
ﬁndings converge with cell biology and animal experi-
ments to support the research and development of ther-
apies targeting semaphorins as neuroprotection for PD.
Several additional ﬁndings of the whole-genome scan
are consistent with our current understanding of PD
(table 4). One of the replicated SNPs mapped the
PARK11 locus, which showed signiﬁcant linkage to
PD in one study but not in another (Pankratz et al.
2003; Prestel et al. 2005). Another replicated SNP was
within the cancer-related UDP-N-acetyl-a-D-galactos-
amine:polypeptide N-acetylgalactosaminyltransferase 3
gene (GALNT3 [MIM 601756]). This may be consis-
tent with epidemiological studies that suggest that pa-
tients with PD have a higher risk of cancers after the
diagnosis of PD (Elbaz et al. 2005). Another replicated
SNP was within the PR domain–containing protein 2
gene (PRDM2 [MIM 601196]), which is also related to
neuronal differentiation and cancer. That gene is also
estrogen related. This may be consistent with epide-
miological data suggesting that endogenous estrogen
and estrogen treatment are protective against PD (Be-
nedetti et al. 2001). Finally, a replicated SNP was within
the chromosome X gene PASD1 (PAS domain–contain-
ing 1). X inactivation of a major susceptibility gene
could explain the sex difference in lifetime risk of PD
(men have a 1.5-times-greater risk than women) (Elbaz
et al. 2002; Carrel and Willard 2005).
Our tier 2b, hypothesis-based SNP analyses were
noteworthy for highlighting a chromosome 1p32 locus
previously linked to late-onset PD susceptibility. The
PARK10 locus was originally identiﬁed in Icelandic fami-
lies via a genomewide scan with use of microsatellite
markers (Hicks et al. 2002). This locus was subse-
quently shown to inﬂuence age at onset in a multicenter
study of families with PD (Li et al. 2002). To date, a
speciﬁc gene within the PARK10 locus has not been
identiﬁed. Our disease-associated SNPs (rs682705 and
rs7520966) are within a gene designated LOC200008,
which encodes a hypothetical protein with inferred oxi-
doreductase activity and potential involvement in cho-
lesterol biosynthesis and electron transport. The SNPs
are also within 21 kb upstream of the mitochondrial
ribosomal protein L37 gene (MRPL37). Mitochondrial
mechanisms of PD pathogenesis have been described
(Dauer and Przedborski 2003), and a role for mito-
chondrial ribosomal protein genes in human disorders
has been postulated (Kenmochi et al. 2001).
To our knowledge, our study is the ﬁrst high-reso-
lution, whole-genome association study published about
PD. Recent review articles anticipated such studies
(Hirschhorn and Daly 2005; Wang et al. 2005), but our
present understanding of human genome variability and
the available high-throughput genotyping technologies
currently allow for whole-genome studies (Patil et al.
2001; Olivier et al. 2001; Hinds et al. 2005). Also, our
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two-tiered study design had several strengths. First, we
performed a family-based case-control study (tier 1).
This limited false-positive results due to population
stratiﬁcation bias (Maraganore 2005). However, the re-
latedness of cases and siblings may have reduced sta-
tistical power to detect genetic associations (false-nega-
tive results). Second, we performed a case–unrelated
control study (tiers 2a and 2b). The use of unrelated
controls (rather than unaffected siblings) optimized sta-
tistical power for the replication study (Maraganore
2005). It is noteworthy that, for tier 2, there was mini-
mal population structure, despite the inclusion of un-
related cases and controls. This is fortunate, since we
therefore did not need to stratify the analyses for the
tier 2 sample. It is also a strength of our study that all
subjects were individually genotyped (no pooling of
DNA samples was involved). This allowed analyses ad-
justed or stratiﬁed for age and sex, factors that have
been shown elsewhere to inﬂuence heritability in PD
(Rocca et al. 2004; Mueller et al. 2005). Individual ge-
notyping will also allow us to perform studies of com-
plex gene-gene and gene-environment interactions and
genotype-phenotype correlations within the available
data set. It is intriguing that 7 of the 11 replicated
SNPs are intergenic. This may suggest that intergenic
sequences are important to health, perhaps via gene
regulatory effects (Martens et al. 2004).
It is likely that the number of SNPs genotyped—or
the speciﬁc ones selected—as well as the available sam-
ple size resulted in our missing disease-associated loci
across the human genome (Carlson et al. 2003, 2004;
Wang et al. 2005). However, we observed an association
of SNPs neighboring the 11 replicated SNPs (“cluster-
ing”), which suggests that we achieved an appreciable
map density. Also, with the available samples, we de-
tected signiﬁcant ( ) ORs 1.34 in tier 1, 1.33P ! .01
in tier 2a, and 1.21 in the combined analysis. It is
also likely that multiple statistical comparisons or other
factors resulted in false-positive ﬁndings (Storey and
Tibshirani 2003; Hirschhorn and Daly 2005). None of
our results were signiﬁcant with use of a strict Bonfer-
roni correction for the number of tests (198,345 SNPs
for tier 1 and the combined analyses, 1,466 SNPs for
tier 2a, and 1,312 SNPs for tier 2b). However, this is a
very conservative evaluation of signiﬁcance; it assumes
total independence of the tests, and properly correcting
for the correlational structure among the SNPs is not
straightforward. Eleven SNPs had P values !.01 and the
same direction of the effect in both tiers 1 and 2a, and
many of these SNPs have compelling potential biologi-
cal relationships with PD or are in regions otherwise
implicated in PD via linkage analysis (“convergence”).
The results of this study draw a ﬁrst genomic map of
PD, which awaits replication across populations (includ-
ing collaborative-pooled analyses within global consor-
tia). Our ﬁndings may ultimately identify biomarkers
that contribute to early disease detection and primary
prevention strategies. Also, they may nominate newmo-
lecular targets for disease-modifying therapies (second-
ary prevention). Correlation studies of genotypes to
prognostic outcomes may predict the effect of treat-
ments targeting these genes and their proteins (“virtual
clinical trials”) and thus reduce research and develop-
ments costs and identify subgroups of patients most
likely to beneﬁt from treatment (personalizedmedicine).
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